Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

With COVID-19, we have a unique opportunity and need to deregulate buprenorphine prescriptions

Megana Dwarakanath, MD
Meds
May 16, 2020
37 Shares
Share
Tweet
Share

My patient was a young man who wanted to be placed back on buprenorphine. He had started using again. He often missed appointments, did not pick up phone calls. So when I saw him in the room, I masked my surprise. “What makes you want to start today?” I asked. “I live with my grandma,” he said. He could not keep leaving the house for heroin.

Of the many issues that undergird health care delivery in the age of COVID-19, medications for addiction treatment (MAT) is one of the most compelling alarms for broader structural changes during and after this pandemic. I work in a clinic that serves as a medical home for people who have interfaced with the juvenile justice system. As jails and group homes try to lessen their numbers, the number of patients who need to connect with care for the first time only increases — as does the demand to start or continue MAT.

In my pre-pandemic haze, I saw the control of buprenorphine scripts to be a kind of boon to ensuring longitudinal care. There was an incentive for patients to come to their appointments, during which time they revealed their career goals, the desire to start families, fears of dying. MAT was a bridge towards a trusting relationship with a provider.

Now, the feeling of a boon has given way to the feeling of unfettered bureaucracy.  Even as opioid overdose is the leading cause of accidental death, buprenorphine remains a tightly regulated drug. Providers need to complete an 8-hour training course in order to obtain a prescription waiver, and there are a limited number of patients providers can treat — 30 in the first year and a maximum of 275.

With COVID-19, we have both the unique opportunity and need to deregulate buprenorphine prescriptions. The Substance Abuse and Mental Health Services Administration (SAHMSA) recently updated guidelines for buprenorphine prescriptions. There are new provisions for telephonic initiation of buprenorphine and scripts up to 28 days for stable patients. Unfortunately, this does not circumvent the major issue: redeployed providers will not be able to fill scripts. With just 7 percent of providers nationally able to even prescribe buprenorphine, this is a particularly vulnerable window for care. We must instead take the current crisis as an opportunity to reform and strengthen MAT access.

First, developing mechanisms for rapid access is critical: not all pharmacies have the capacity to accept electronic scripts for controlled substances. This is an easy means to ensure that patients do not have to leave their homes for prescription pick-ups. Statewide databases for prescription monitoring can make it easy to safely refill buprenorphine, especially when patients are least likely to leave the state. We should also enable telephonic refills. Pharmacists can be trained in accepting security questions from providers prior to filling scripts. Another potential solution is to have providers give their patients a pin number to refill prescriptions should the provider be redeployed or ill. A corollary effect may be improving patient self-efficacy, especially for young people who are more likely to be in transient housing situations where adult oversight is limited.

Second, we need to expand training for buprenorphine initiation and management. With a dearth of addiction medicine in medical education, we limit trainees from becoming interested and, therefore, involved in times of crisis. Expansions in the number of patients are contingent upon oversight from those already with a waiver — a bottleneck effect on rapid training. Given the number of furloughed mid-level practitioners, we could use this time to build capacity for MAT management. SAHMSA has issued some flexibility to permit certified mid-levels to prescribe MAT without direct physician supervision. The need for MAT access will continue to rise, compounded by the reorganization of treatment facilities and detention centers. Our clinic is already finding itself overwhelmed with an uptick of referrals. We are left telling families and patients to wait: we don’t have enough providers, we need to space out visits. And every week, we forego the opportunity to intervene sooner and keep our highest patients at home.

Third, we need to liberalize the length of prescriptions. Prior to COVID-19, buprenorphine prescriptions were dispensed for 14 days. Under new guidance from SAHSMA, scripts can be extended to 28 days — a thoughtful, but incomplete solution. Instead, we need to consider patients on a case by case basis and allow patients to have a refill. Barriers to care, such as housing instability, unemployment, and transportation mean patients are at increased danger of not being able to connect with a provider. While there is a risk of hoarding or diversion, the cost is minimal compared to having a patient return to the streets for heroin.

Structural inequities undergird so much of opioid use disorder: They create, enforce, and exacerbate it. If we were blind to it before, we are now acutely aware that our personal choices are both created and limited by our biases. We don’t need to wait for a pandemic to end before we re-envision both our choices and our beliefs.

Megana Dwarakanath is a pediatric resident.

Image credit: Shutterstock.com

Prev

Don’t drink the COVID conspiracy Kool-Aid

May 16, 2020 Kevin 5
…
Next

Is a new coronavirus already here?

May 16, 2020 Kevin 1
…

Tagged as: COVID, Infectious Disease, Psychiatry

Post navigation

< Previous Post
Don’t drink the COVID conspiracy Kool-Aid
Next Post >
Is a new coronavirus already here?

More by Megana Dwarakanath, MD

  • With COVID-19, a need to deregulate buprenorphine prescriptions [PODCAST]

    Megana Dwarakanath, MD

Related Posts

  • COVID-19 can be an opportunity to eliminate low-value health care 

    Karen Born, PhD and Ken Milne, MD
  • How to get patients vaccinated against COVID-19 [PODCAST]

    The Podcast by KevinMD
  • COVID-19 divides and conquers

    Michele Luckenbaugh
  • State sanctioned executions in the age of COVID-19

    Kasey Johnson, DO
  • A patient’s COVID-19 reflections

    Michele Luckenbaugh
  • Starting medical school in the midst of COVID-19

    Horacio Romero Castillo

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Nose-brain connection: The surprising link between allergies and mental health revealed

      Kara Wada, MD | Conditions
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
  • Recent Posts

    • Unconventional health care, flawed studies, and biases: Navigating the complexities for optimal well-being

      Kara Wada, MD | Physician
    • Urgent innovation needed to address growing mental health crisis among children and families

      Monika Roots, MD | Conditions
    • The importance of listening in health care: a mother’s journey advocating for children with chronic Lyme disease

      Cheryl Lazarus | Conditions
    • Medical errors and the power of apologies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Finding your ideal work-life balance: tips for prioritizing personal life and achieving professional success

      Zahid Awan, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 3 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • TAR-200 Led to High Complete Response Rates in BCG-Unresponsive Bladder Cancer
  • More Success for CAR T-Cell Therapy in Rheumatic Disease
  • Nurse Accused of Killing Patients With Insulin; Naturopath Settles False Claims Suit
  • JAK Inhibitor Shows Promise in Severe Type of Sclerosis
  • Adaptive RT Fails to Relieve Dry Mouth in Head and Neck Cancer

Meeting Coverage

  • TAR-200 Led to High Complete Response Rates in BCG-Unresponsive Bladder Cancer
  • More Success for CAR T-Cell Therapy in Rheumatic Disease
  • Trial Shows RA Can Be Stopped at Preclinical Stage
  • Tenapanor Improves Abdominal Symptoms in Patients With IBS-C
  • Benefits Found for Hand OA Drug Treatments
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Nose-brain connection: The surprising link between allergies and mental health revealed

      Kara Wada, MD | Conditions
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
  • Recent Posts

    • Unconventional health care, flawed studies, and biases: Navigating the complexities for optimal well-being

      Kara Wada, MD | Physician
    • Urgent innovation needed to address growing mental health crisis among children and families

      Monika Roots, MD | Conditions
    • The importance of listening in health care: a mother’s journey advocating for children with chronic Lyme disease

      Cheryl Lazarus | Conditions
    • Medical errors and the power of apologies [PODCAST]

      The Podcast by KevinMD | Podcast
    • Finding your ideal work-life balance: tips for prioritizing personal life and achieving professional success

      Zahid Awan, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

With COVID-19, we have a unique opportunity and need to deregulate buprenorphine prescriptions
3 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...